Inclisiran: what it treats, how it is given, side effects
Last updated September 3, 2026.
Inclisiran (brand name Leqvio) is the twice-a-year cholesterol injection: a small-interfering-RNA drug that tells the liver to make less PCSK9. After the first two doses, it is given every 6 months by a healthcare professional, which makes it the lowest-maintenance LDL-lowering therapy that exists.
What does it treat?
High LDL cholesterol alongside diet and exercise: in adults with established cardiovascular disease or high risk, including heterozygous familial hypercholesterolemia, when maximally tolerated statins have not gotten LDL to goal. Where PCSK9 antibodies like evolocumab block the protein after it is made, inclisiran silences the gene that makes it, upstream.
How do you take it?
You do not self-inject it: a doctor or nurse gives the 284 mg subcutaneous injection at a clinic. The schedule is the entire story: day 0, again at 3 months, then every 6 months thereafter. Two maintenance visits a year. In trials, that schedule cut LDL-C by about 50 to 52% from baseline, sustained, on top of statins. Missed doses are rescheduled with your clinic rather than doubled.
Side effects to know
- Common: injection-site reactions (pain, redness, swelling), joint pain, and cough or chest-tightness symptoms in a minority.
- Serious: hypersensitivity reactions have been reported; a serious allergic reaction means stopping the drug. Otherwise its safety profile in trials tracked close to placebo, which is remarkable for a drug this potent.
Who should not take it?
Anyone with a prior serious hypersensitivity reaction to it. Pregnancy and breastfeeding lack data, so that is a clinician conversation, and cholesterol drugs generally pause in pregnancy. It is an add-on, not a statin replacement: the patients it was studied in were on maximally tolerated statins. Since it is clinic-administered, adherence problems essentially vanish, which is half the point.
When is it an emergency?
Call 911 for facial or throat swelling, trouble breathing, or a severe spreading rash after an injection. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
Twice a year, really?
Really. After the day-0 and 3-month loading doses, it is one clinic injection every 6 months. The drug works by silencing the PCSK9 gene inside liver cells, and each dose does that for months. For people whose cholesterol pills fail through forgetting, this is the structural fix.
How much does it lower LDL?
About 50 to 52% from baseline in the ORION trials, sustained across the 6-month dosing interval, on top of maximally tolerated statins. That is in the same league as the every-2-weeks PCSK9 antibody injections, traded for far fewer needle days.
siRNA sounds like gene therapy. Is it?
No. It does not touch your DNA. Small interfering RNA is a short-lived molecular instruction that degrades the PCSK9 messenger RNA in liver cells, temporarily reducing production of one protein. It wears off, which is why you get re-dosed every 6 months.
Why is it given at a clinic instead of at home?
The label has it administered by a healthcare professional, and that is partly the design: it turns adherence from a daily burden into two calendar appointments, and it removes storage, sharps, and self-injection technique from your life. The trade is scheduling around clinic visits.
Does it replace my statin?
No. It was studied as an add-on to maximally tolerated statins, and the statin underneath keeps working. Stopping the statin because the injection exists is not the model. Think of it as the twice-yearly booster on a daily foundation.
How does it compare to the PCSK9 shots like Repatha?
Same LDL ballpark (about half off), opposite lifestyles: Repatha and Praluent are self-injected every 2 weeks or monthly at home; inclisiran is clinic-given twice a year. Outcome trials proving event reduction exist for the antibodies; inclisiran's big outcomes trial is still running, so for post-heart-attack patients the antibodies have the firmer event data today.